WO2015100799A1 - β-扁柏酚衍生物及其在制备动物专用抗菌剂以及饲用抗菌生长促进剂中的应用 - Google Patents

β-扁柏酚衍生物及其在制备动物专用抗菌剂以及饲用抗菌生长促进剂中的应用 Download PDF

Info

Publication number
WO2015100799A1
WO2015100799A1 PCT/CN2014/070603 CN2014070603W WO2015100799A1 WO 2015100799 A1 WO2015100799 A1 WO 2015100799A1 CN 2014070603 W CN2014070603 W CN 2014070603W WO 2015100799 A1 WO2015100799 A1 WO 2015100799A1
Authority
WO
WIPO (PCT)
Prior art keywords
added
temperature
water
organic phase
stirring
Prior art date
Application number
PCT/CN2014/070603
Other languages
English (en)
French (fr)
Inventor
彭险峰
覃宗华
Original Assignee
广州英赛特生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州英赛特生物技术有限公司 filed Critical 广州英赛特生物技术有限公司
Priority to CA2934581A priority Critical patent/CA2934581A1/en
Priority to BR112016013801A priority patent/BR112016013801A2/pt
Priority to EP14875937.6A priority patent/EP3085685A4/en
Priority to US15/108,726 priority patent/US20160316790A1/en
Publication of WO2015100799A1 publication Critical patent/WO2015100799A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/717Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups a keto group being part of a seven- to twelve-membered ring
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N35/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
    • A01N35/04Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aldehyde or keto groups, or thio analogues thereof, directly attached to an aromatic ring system, e.g. acetophenone; Derivatives thereof, e.g. acetals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/111Aromatic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/195Antibiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/70Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75Feeding-stuffs specially adapted for particular animals for birds for poultry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/18Systems containing only non-condensed rings with a ring being at least seven-membered

Definitions

  • the invention belongs to the field of livestock and poultry breeding, and particularly relates to a ⁇ - cedar phenol derivative and its application in preparing an animal-specific antibacterial agent and serving an antibacterial growth promoter. Background technique:
  • hinokitiol also known as hinokitiol, eucalyptus, and ketone (phenol), chemical name: 2-hydroxy-4-isopropyl-1-cycloheptenone, is natural
  • the essential oil component has been used as a food additive in Japan for many years.
  • U.S. Patent No. 6,387,417 B1 discloses the activity of ⁇ - hinokol and its complex (2:1 or 3:1) against vancomycin-resistant enterococci and its use in therapy. Summary of the invention:
  • a first object of the present invention is to provide a ⁇ - cefophenol derivative which has broad-spectrum antibacterial activity and can be used as an animal-specific antibacterial agent and as an antibacterial growth promoter.
  • the ⁇ - hinokol derivative of the present invention has a structural formula of the formula (I):
  • R is n-propyl, n-pentyl, benzyl, sec-butyl, ethyl, n-butyl, p-chlorobenzyl, p-fluorobenzyl, n-octyl, 1-fluoropropyl or n-tetradecyl .
  • the present invention has found through experiments that the ⁇ - cypressol derivative of the present invention has a broad spectrum of antibacterial activity, and is an important pathogenic bacteria to animals (such as Clostridium perfringens, Staphylococcus aureus, Escherichia coli, Salmonella, and duck plague). Mercera, Haemophilus parasuis, Vibrio and Streptococcus, etc. all showed good inhibitory activity, especially the derivatives IST_009_001 and IST_009_003 had stronger antibacterial activity than the lead compound ⁇ _001_002 ( ⁇ - hinokol).
  • a second object of the present invention is to provide an application of any of the above-mentioned ?- cedar derivatives in the preparation of an animal-specific antibacterial agent or a service antibacterial growth promoter.
  • the animals are pigs, chickens, ducks, geese, beef cattle, cows, sheep, fish, shrimps, etc. at various stages of growth. Animals such as foxes, crickets or crickets.
  • the ⁇ - cefophenol derivative has an additive amount of 0.1 to 200 ppm of an animal feed in an animal feed.
  • the animal-specific antibacterial agent is used for treating diseases caused by infection of various animal sensitive bacteria, and the application amount thereof is l-30 mg/kg body weight.
  • the compound of the present invention as shown in Formula 1 is less toxic or non-toxic to livestock and poultry, and has higher safety and stronger growth promoting performance than the current patent covering compound, and thus is more suitable as a growth promoter for the feedstock. , has a very good application prospect in the breeding industry. detailed description:
  • the present invention relates to 11 ⁇ - cypressol derivatives, the structural formula of which is as follows:
  • the first step is a first step:
  • the temperature was lowered to about -10 ° C, and a mixed solution of 150 ml of n-hexane and n-propyl bromide (0.8 to 1.2 eq) was added dropwise to the three-necked bottle for about lh, and the control temperature was not higher than 20 °C.
  • the natural temperature is continued to react for more than 1 h, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is thoroughly stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane, and the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the first step is a first step:
  • the temperature was lowered to about -10 ° C, and a mixed solution of 150 ml of n-hexane and 1-bromopentane (0.8 to 1.2 eq) was added dropwise to the three-necked bottle for about 1 hour, and the control temperature was not higher than 20 ° C.
  • the natural temperature is continued to react for more than 1 h, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is thoroughly stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane, and the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the first step is a first step:
  • the temperature was lowered to about -10 °C, and a mixed solution of 150 ml of n-hexane and benzyl bromide (0.8 to 1.2 eq) was added dropwise to the three-necked bottle for about lh, and the control temperature was not higher than 20 °C.
  • the natural temperature is continued to react for more than lh, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is fully stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane.
  • the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the first step is a first step:
  • the temperature was lowered to about -10 ° C, and a mixed solution of 150 ml of n-hexane and 2-bromobutane (0.8 to 1.2 eq) was added dropwise to the three-necked bottle for about 1 hour, and the control temperature was not higher than 20 ° C.
  • the natural temperature is continued to react for more than 1 h, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is thoroughly stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane, and the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the second step Under stirring, add dichloroacetyl chloride (0.7 ⁇ 1.5 eq) to n-hexane solution of sec-butylcyclopentadiene, and cool down to -15 ⁇ 10 °C to add triethylamine (0.8 ⁇ 1.5 eq). More than 15 ° C, about 1 hour drop, continue to heat the reaction for 1h, then add dilute hydrochloric acid to adjust the pH neutral or slightly acidic, stir for 5 ⁇ 10min, then liquid, TLC (developing agent: PE) check the organic phase and the aqueous phase The product situation. Then, the organic phase is rotary evaporated to remove the solvent at a water temperature of about 35 ° C, and the obtained green residual liquid is dichlorobicyclo ketone.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the petroleum ether was added after cooling to below 40 ° C, a large amount of solid was precipitated, the clear liquid was poured out, the solid was washed once with petroleum ether, the organic phase was filtered off, the organic phase was combined, and the solid was discarded.
  • the organic phase was washed by adding about 200 ml of distilled water, the layers were extracted, and the aqueous phase was discarded.
  • the organic solvent was spin-dried, and the residue was evaporated under reduced pressure to give a vacuum of -0.099 and a bath temperature of 170-175 Q C, and a fraction temperature of 100-111 Q C.
  • the received fraction was dissolved in 150 ml of petroleum ether and cooled from room temperature to -25 Q C using a low temperature reactor. White crystals were precipitated, filtered, and the solid was rapidly melted. The oil was washed with petroleum ether to give a white solid. It is 2-hydroxy-5-sec-butyl-2,4,6-cycloheptatrien-1-one. The solvent was dried to give 2-hydroxy-4-sec-butyl-2,4,6-cycloheptatrione and 2-hydroxy-5-sec-butyl-2,4,6-cycloheptatrione.
  • the first step is a first step:
  • the natural temperature is continued to react for more than lh, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is fully stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane.
  • the organic layer is combined and washed with water 250 ml ⁇ 2.
  • Neutral to the aqueous phase dried 40g anhydrous sodium sulfate until the liquid is clear, the solid is filtered off, the organic phase (about 400ml) is added to a 1000ml three-necked bottle, and it is allowed to be isomerized by standing at 20 ⁇ 2°C for 7 ⁇ 20hr.
  • the isomerization was measured by GC, whereby ethylcyclopentadiene was obtained.
  • dichloroacetyl chloride (0.7 ⁇ 1.5 eq) was added to the n-hexane solution of ethylcyclopentadiene, and the temperature was lowered to -15 ⁇ 10 °C, and triethylamine (0.8 ⁇ 1.5 eq) was added dropwise to control the temperature. Not more than 15 °C, about 1hr drop, continue the heat preservation reaction for 1h, then add diluted hydrochloric acid to adjust the pH neutral or slightly acidic, stir for 5 ⁇ 10min, then separate the liquid, TLC (developing agent: PE) check the organic phase and the water phase The product in the case.
  • TLC developer: PE
  • the organic phase is rotary evaporated to remove the solvent at a water temperature of about 35 ° C, and the resulting residual liquid is dichlorobicyclo ketone.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the first step is a first step:
  • the temperature was lowered to about -10 °C, and a mixed solution of 150 ml of n-hexane and n-bromobutane (0.8 to 1.2 eq) was added dropwise to the three-necked bottle for about lh, and the control temperature was not higher than 20 °C.
  • the natural temperature is continued to react for more than 1 h, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is thoroughly stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane, and the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the temperature was lowered to 40 ° C or lower, 200 ml of ethyl acetate, 200 ml of water + 10 ml of concentrated hydrochloric acid was added, the layers were extracted, the aqueous phase was discarded, and the organic phase was washed twice with 200 ml of water.
  • the organic solvent was spin-dried, and the residue was distilled under reduced pressure, pressure-O. lMPa, external temperature 150 to 180 Q C, fraction temperature 115 to 120 Q C, to obtain about 25 g of product, and the product was dissolved in 150 ml of n-hexane and 10 ml of ethanol.
  • the first step is a first step:
  • the temperature was lowered to about -10 ° C, and a mixed solution of 150 ml of n-hexane and p-chlorobenzyl bromide (0.8 to 1.2 eq) was added dropwise to the three-necked bottle for about 1 hour, and the control temperature was not higher than 20 ° C.
  • the natural temperature is continued to react for more than 1 h, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is thoroughly stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane, and the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the organic phase is rotary evaporated at a water temperature of about 35 ° C to remove the solvent, and the obtained residual liquid is dichlorobicyclo ketone.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the first step is a first step:
  • the time is about lh, and the control temperature is not higher than 20 °C.
  • the natural temperature is continued to react for more than 1 h, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is thoroughly stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane, and the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the first step is a first step:
  • the temperature was lowered to about -10 ° C, and a mixed solution of 150 ml of n-hexane and n-bromooctane (0.8 to 1.2 eq) was added dropwise to the three-necked bottle for about lh, and the control temperature was not higher than 20 °C.
  • the natural temperature is continued to react for more than 1 h, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is thoroughly stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane, and the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the first step is a first step:
  • a mixed solution of 150 ml of n-hexane and 1-fluoro-3-bromopropane (0.8 to 1.2 eq) is added dropwise to the three-necked bottle for about lh, and the control temperature is not higher than 20°. C.
  • the natural temperature is continued to react for more than lh, then the pH is adjusted to be acidic by adding dilute hydrochloric acid. After the adjustment, the mixture is stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane. The organic layer is combined and washed with water 250 ml ⁇ 2.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • the first step is a first step:
  • the temperature was lowered to about -10 ° C, and a mixed solution of 150 ml of n-hexane and bromotetradecane (0.8 to 1.2 eq) was added dropwise to the three-necked bottle for about lh, and the control temperature was not higher than 20 °C.
  • the natural temperature is continued to react for more than 1 h, then the pH is adjusted to be acidic by adding dilute hydrochloric acid, and the mixture is thoroughly stirred for 5 to 10 minutes, and then the liquid layer is separated again with 150 ml of n-hexane, and the organic layer is combined and washed with water 250 ml ⁇ 2.
  • the 1000 ml three-necked flask with the condensation tube was added with the dichlorobicyclo ketone prepared in the previous step, and then 125 ml of t-butanol, 20 ml of acetic acid and 25 ml of water were successively added thereto, and the mixture was heated to 75 to 80 ° C with stirring, and 85 ml (98%, 0.675 mol) was added thereto.
  • Example 12 In vitro antibacterial activity (MICs) of p- cedar derivatives
  • the in vitro minimum inhibitory concentration of the ⁇ - cetophenol series derivatives against different types of bacteria was determined by test tube double dilution method.
  • the results are shown in Tables 1, 2, 3 and 4, and Tables 1, 2, 3 and 4 show that ⁇ - cedar phenol derivatives have a broad spectrum of antibacterial activity, and are important pathogenic bacteria to animals (such as Clostridium perfringens, Staphylococcus aureus, Escherichia coli, Salmonella, R. anatipestii, Haemophilus parasuis, Vibrio and Streptococcus, etc. all showed good inhibitory activity, especially the antibacterial activities of derivatives such as IST_009_001 and IST_009_003 Stronger than the lead compound IST_001_002 ( ⁇ - hinokitiol).
  • Table 2 Minimum inhibitory concentration of ⁇ - cetophenol derivatives against Escherichia coli and Salmonella in vitro (MIC, g/ml)
  • Example 13 Application effect of p- cypressol derivative in broiler feed
  • Example 14 Control effect of P- cypressol derivatives on diarrhea in weaned piglets
  • Example 15 Protective effect of P- cypressol derivatives on R. anatipestifer challenge
  • Table 8 The effect of cypressol derivatives on the infection of Riemer's two bacteria attack

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Birds (AREA)
  • General Health & Medical Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Fodder In General (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

一种β-扁柏酚衍生物及其在制备动物专用抗菌剂以及伺用抗菌生长促进剂中的应用。β-扁柏酚衍生物,其结构式如式(I)所示:其中R为正丙基、正戊基、苄基、仲丁基、乙基、正丁基、对氯苄基、对氟苄基、正辛基、1-氟丙基或正十四烷基。

Description

P-扁柏酚衍生物及其在制备动物专用抗菌剂以及饲用抗菌生长促进剂中的应用 技术领域:
本发明属于畜禽养殖领域,具体涉及 β-扁柏酚衍生物及其在制备动物专用抗 菌剂以及伺用抗菌生长促进剂中的应用。 背景技术:
β-扁柏酚(β-hinokitiol), 又名扁柏醇、桧木醇、 日柏醇(酚)等名,化学名: 2-羟基 -4-异丙基 -1-环庚三烯酮, 是天然食用精油组分, 在日本已用作食品添加 剂多年。
US6387417B1有公开 β-扁柏酚及其配合物(2:1或 3:1 )抗万古霉素耐药肠球 菌的活性及其在治疗中的应用。 发明内容:
本发明的第一个目的是提供具有广谱抗菌活性,能够作为动物专用抗菌剂和 伺用抗菌生长促进剂应用的 β-扁柏酚衍生物。
本发明的 β-扁柏酚衍生物, 其结构式如式 ( I ) 所示:
Figure imgf000002_0001
( I )
其中 R 为正丙基、 正戊基、 苄基、 仲丁基、 乙基、 正丁基、 对氯苄基、 对 氟苄基、 正辛基、 1-氟丙基或正十四烷基。
具体的结构式如下所示:
Figure imgf000003_0001
Exact Mass: 192.12 Exact Mass: 212.08
Exact Mass: 164.08 1ST— 009— 003 IST—009— 004
1ST— 009— 001
Figure imgf000003_0002
Exact Mass: 150.07
Exact Mass: 178.10 1ST— 009— 018
1ST— 009— 008
Exact Mass: 246.04 Exact Mass: 230.07
Exact Mass: 178.10 1ST— 009— 025 IST—009— 028
1ST— 009— 019
Figure imgf000003_0003
Exact Mass: 234.16 Exact Mass: 318.26
Exact Mass: 182.07
1ST— 009— 030 ISTJ09J33
1ST— 009— 031
本发明通过实验发现, 本发明的 β-扁柏酚衍生物具有广谱的抗菌活性, 对动 物重要病原性细菌 (如产气荚膜梭菌、 金黄色葡萄球菌、 大肠杆菌、 沙门氏菌、 鸭疫里默氏杆菌、 副猪嗜血杆菌、 弧菌和链球菌等) 均表现出很好的抑制活性, 尤其是衍生物 IST_009_001和 IST_009_003等的抗菌活性强于先导化合物 ΚΤ_001_002 ( β-扁柏酚)。并且肉鸡伺喂实验发现, β-扁柏酚衍生物 IST_009_001 和 IST_009_003等能提高试验鸡的增重和伺料转化效率。 断奶仔猪伺喂实验发 现, 在伺料中添加 IST_009_001可以显著降低试验猪的腹泻率, 且 IST_009_001 的效果较 IST_001_002好。
因此本发明的第二个目的是提供上述 β-扁柏酚衍生物中的任意一种在制备 动物专用抗菌剂或伺用抗菌生长促进剂中的应用。
所述的动物为各个生长阶段的猪、 鸡、 鸭、 鹅、 肉牛、 奶牛、 羊、 鱼、 虾、 狐、 貂或貉等动物。
所述的 β-扁柏酚衍生物,其在动物伺料中的添加剂量为 0.1〜200ppm动物伺 料。
所述的动物专用抗菌剂为治疗各种动物敏感菌感染导致的疾病时,其应用剂 量为 l-30mg/kg体重。
本发明的如式 1所示的化合物对畜禽低毒或者无毒,其比目前专利覆盖相关 化合物有更高的安全性及更强的生长促进性能,因此更适合作为伺料用生长促进 剂, 在养殖行业具有非常好的应用前景。 具体实施方式:
以下实施例是对本发明的进一步说明, 而不是对本发明的限制。
本发明涉及的 11个 β-扁柏酚衍生物, 其结构式如下所示:
Figure imgf000004_0001
Exact Mass: 192.12 Exact Mass: 212.08
Exact Mass: 164.08 1ST— 009— 003 IST—009— 004
1ST— 009— 001
Figure imgf000004_0002
Exact Mass: 150.07 Mass: 178.10 1ST— 009— 018 1ST— 009— 008
Exact Mass: 246.04 Exact Mass: 230.07
Exact Mass: 178.10 1ST— 009— 025 IST—009— 028 1ST— 009— 019
Figure imgf000005_0001
Exact Mass: 234.16 Exact Mass: 318.26
Exact Mass: 182.07
1ST— 009— 030 ISTJ09J33
1ST— 009— 031
实施例 1: IST_009_001 (2-羟基 -4-正丙基 -2, 4, 6-环庚三熾 -1-酮) 的合成
Figure imgf000005_0002
2-羟基 -4-正丙基 -2, 4, 6-环庚三烯小酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以致换瓶中空气。 N2保护下加入氢氧化钾(0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体 (0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和正丙基溴 ( 0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升 温继续反应 lh以上, 然后流加稀盐酸调 pH至酸性, 调毕, 充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 良好, 由此得到正丙基环戊二烯。
第二步:
搅拌下, 往正丙基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15 °C, 约 lhr 滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜10min 后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有机相在 35 °C左右水温下旋蒸除去溶媒, 得到的绿色残留液即为二氯双环酮。
第三步:
具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40°C以下后加入 300ml二氯甲烷, 有大量固体析出, 然后 流加稀盐酸调 pH至酸性。调毕,搅拌 5〜 1 Omin后倒出有机相,瓶中固体用 100ml 二氯甲烷洗涤之后倒出有机相, 合并有机相, 然后加入 3M的氢氧化钾水溶液, 产物溶解在水相中, 二氯甲烷层点板, 显示为杂质点, 没有产物点, 萃取分液, 弃去有机层, 水相用石油醚再洗涤一遍。然后往水相中加入石油醚, 搅拌下在混 合液中加入 3M的盐酸水溶液中和至酸性, 弃去水相, 有机相再用水洗涤 3遍, 有机相点板 (PE:EA=5: 1 ) 为一个点, NMR鉴定物质, 其为 2-羟基 -4-正丙基 -2,
4, 6-环庚三烯 -1-酮, 结构式为:
Figure imgf000006_0001
2-羟基 -4-正丙基 -2, 4, 6-环庚三烯 -1-酮: SH (DMSO, 500 MHz) 7.271-7.313 (1H m),7.144(lH,s),7.073-7.095(lH,d,J=l l),6.912-6.932(lH,d,J=10),2.530-2.560(2H,m), 1.544-1.618 (2H,m), 0.867-0.896(3H,m)。
003 (2-羟基 -4-戊基 -2, 4, 6-环庚三烯 -1-酮) 的合成
Figure imgf000006_0002
2-羟基 -4-戊基 -2, 4, 6-环庚三烯 -1-酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以致换瓶中空气。 N2保护下加入氢氧化钾(0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体 (0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和 1-溴戊烷 ( 0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升 温继续反应 lh以上, 然后流加稀盐酸调 pH至酸性, 调毕, 充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 由此得到正戊基环戊二烯。
第二步:
搅拌下, 往正戊基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15°C, 约 lhr 滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜10min 后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有机相在 35°C左右水温下旋蒸除去溶媒, 得到的绿色残留液即为二氯双环酮。
第三步:
具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40°C以下后加入 300ml二氯甲烷, 有大量固体析出, 然后 流加稀盐酸调 pH至酸性。调毕,搅拌 5〜10min后分液, TLC (展开剂: EA:PE=1 :5 ) 检查水层无产物后弃去, 有机相 (下层)用 40g无水硫酸钠干燥 15min, 滤除固 体, 然后在 35〜38°C水浴中减压 (水环泵) 蒸除溶媒, 将残留物升温至 265°C, 高真空蒸馏(使用旋片式真空油泵, -0.098MPa以上), 收集 112〜116°C的馏分。 蒸馏毕, 通氮气卸去真空, 馏份 (约 8g) 在氮气保护下加入 50ml石油醚 TLC (PE:EA=5:1 ) 显示产物上面有两个小杂质点, 产物完全溶解, 放入冰箱 4QC, 没有固体析出, 降低到 -20QC, 出油。
将产物溶解在石油醚中, 然后加入 3M的氢氧化钾水溶液, 产物溶解在水相 中, 石油醚层点板, 显示为杂质点, 没有产物点, 萃取分液, 弃去有机层, 水相 用石油醚再洗涤一遍。然后加入石油醚, 搅拌下在混合液中加入 3M的盐酸水溶 液中和至酸性, 弃去水相, 有机相再用水洗涤 3遍, 有机相点板 (PE:EA=5:1 ) 为一个点, 旋干有机相得产物。 NMR鉴定物质, 其为 2-羟基 -4-戊基 -2, 4, 6-
Figure imgf000007_0001
2-羟基 -4-戊基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.269-7.310 (1H, m) 7.142(lH,s),7.071-7.093(lH,d,J=l l),6.912-6.932(lH,d,J=10),2.544-2.575(2H,m),1.5 26-1.584(2H,m), 1.268-1.292(4H,m),0.828-0.854(3H,m)。
004的合成
Figure imgf000008_0001
2-羟基 -4-苄基 -2, 4, 6-环庚三烯小酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以致换瓶中空气。 N2保护下加入氢氧化钾(0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体 (0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和苄溴(0.8〜 1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升温继续 反应 lh以上,然后流加稀盐酸调 pH至酸性,调毕,充分搅拌 5〜10min后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至水相呈中 性, 40g无水硫酸钠干燥至液体澄清,滤除固体,有机相(约 400ml)加入到 1000ml 三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 由此得到苄 基环戊二烯。
第二步:
搅拌下, 往苄基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜1.5eq),降 温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15 °C, 约 lhr滴 完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜10min后 分液, TLC (展开剂: PE)检查有机相和水相中的产物情况。然后有机相在 35 °C 左右水温下旋蒸除去溶媒, 得到的绿色残留液即为二氯双环酮。
第三步:
具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40 °C以下后加入 150ml二氯甲烷, 然后流加稀盐酸 (10ml 浓盐酸十 200ml水)调 pH至酸性。调毕, 搅拌 5〜10min后分液, TLC (展开剂: EA:PE=1 :5 ) 检查水层无产物后弃去, 往有机相 (下层) 中加入 200ml水搅拌下 加入 3M的氢氧化钾水溶液 150ml, 然后萃取, 不分层。 取一半上层液体加入约 200ml石油醚, 萃取分层, 水层再用石油醚洗涤一次, 然后往水层中加入 200ml 石油醚, 搅拌下加入 3M的稀盐酸中和至 PH值 1〜2, 萃取分层, 很快有机层有 固体析出,加入少量乙酸乙酯使固体完全溶解,萃取分液,有机层旋至还剩 50ml 左右, 放入冰箱静置过夜, 有结晶析出, 过滤, 晶体用石油醚洗涤, 得到 2.2克 产品。 NMR鉴定产物,其为 2-羟基 -4-苄基 -2, 4, 6-环庚三烯 -1-酮,其结构式为:
Figure imgf000009_0001
2-羟基 -4-苄基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.303-7.316 (3H m), 7.269-7.283(2H, d,J=7),7.21 l-7.239(lH,m),7.183(lH,s),7.066-7.088(lH,d,J=l l),6.985-7.005 (lH,d,J=10), 3.952(2H,s)。
实施例 4: 1ST 成
Figure imgf000009_0002
2-羟基 -4-仲丁基 -2, 4, 6-环庚三烯 -1-酮及 2-羟基 -5-仲丁基 -2, 4, 6-环庚三 烯 -1-酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以置换瓶中空气。 N2保护下加入氢氧化钾 (0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体 (0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和 2-溴丁烷 ( 0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升 温继续反应 lh以上, 然后流加稀盐酸调 pH至酸性, 调毕, 充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 异构化前后均为两个峰, 由此得到仲丁基环戊二烯。
第二步: 搅拌下, 往仲丁基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15°C, 约 lhr 滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜10min 后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有机相在 35°C左右水温下旋蒸除去溶媒, 得到的绿色残留液即为二氯双环酮。 具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40°C以下后加入石油醚, 有大量固体析出, 倒出澄清液体, 固体再用石油醚洗涤一次, 滤出有机相, 合并有机相, 弃去固体。 往有机相中加 入约 200毫升蒸馏水洗涤, 萃取分层, 弃去水相。 旋干有机溶剂, 残留物减压蒸 馏收集真空度为 -0.099浴温 170-175QC,馏份温度 100-111QC。
收到的馏份溶解在 150毫升石油醚中, 用低温反应器从室温降温至 -25QC, 有白色晶体析出, 过滤, 固体迅速融化, 用石油醚洗涤油状物, 得到白色固体, NMR鉴定为 2-羟基 -5-仲丁基 -2, 4, 6-环庚三烯 -1-酮。 旋干溶剂得到 2-羟基 -4- 仲丁基 -2, 4, 6-环庚三烯小酮和 2-羟基 -5-仲丁基 -2, 4, 6-环庚三烯小酮。
2-羟基 -4-仲丁基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.302-7.344 (1 H, m),7.127(lH,s),7.085-7.106(lH,d,J=10.5),6.097-6.927(lH,d,J=10),2.535-2.604(l H,m),1.503-1.561 (2H,m), 1.152-1.165(3H,d,J=6.5),0.738-0.768(3H,m)
2-羟基 -5-仲丁基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.268-7.291 (2H, d,J=11.5), 7.167-7.191(2H, d,J=12), 2.527-2.614( 1H, m ),1.477-1.584 (2H,m ), 1.153-1.167( 3H,d,J=7 ),0.743-0.773(3H,m)o
实施例 5: 1ST 009 018 (2- , 4, 6-环庚三烯 -1-酮) 的合成
Figure imgf000010_0001
2—羟基—4-乙基 -2, 4, 6-环庚三烯 -1-酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以置换瓶中空气。 N2保护下加入氢氧化钾 (0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体 (0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。后开冷冻降温至 -10°C左右,往三口瓶中滴加正己烷 150ml和溴乙烷(0.8〜 1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升温继续 反应 lh以上,然后流加稀盐酸调 pH至酸性,调毕,充分搅拌 5〜10min后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至水相呈中 性, 40g无水硫酸钠干燥至液体澄清,滤除固体,有机相(约 400ml)加入到 1000ml 三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 由此得到乙 基环戊二烯。
第二步:
搅拌下, 往乙基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜1.5eq),降 温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15 °C, 约 lhr滴 完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜10min后 分液, TLC (展开剂: PE)检查有机相和水相中的产物情况。然后有机相在 35 °C 左右水温下旋蒸除去溶媒, 得到的残留液即为二氯双环酮。 具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40 °C以下后加入 150ml二氯甲烷, 然后流加稀盐酸 (10ml 浓盐酸十 200ml水)调 pH至酸性。调毕, 搅拌 5〜10min后分液, TLC (展开剂: EA:PE=1 :5 ) 检查水层无产物后弃去, 旋干有机层, 然后加入 200ml石油醚, 搅 拌半小时后静置分层, 下层为黑色粘稠液, 上层为深色有机相, 分液, 弃去黑色 粘稠液。 往有机相 (上层) 中加入 200ml水搅拌下加入 3M的氢氧化钾水溶液 150ml, 然后萃取分液。 水层再用石油醚洗涤一次, 然后往水层中加入 200ml石 油醚, 搅拌下加入 3M的稀盐酸中和至 PH值 1〜2, 萃取分液, 有机层再用水洗 涤一次, 旋干有机层得产物。 HPLC显示纯度为 96%, NMR鉴定物质, 其为 2-
羟基 -4-乙基 -2, 4, 6-环庚三烯 -1-酮, 结构式为:
Figure imgf000011_0001
2-羟基 -4-乙基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.271-7.315 (1H, m) 7.144(lH,s),7.072-7.094(lH,d,J=l l),6.917-6.937(lH,d,J=10),2.564-2.609(2H,m),l . l
46-1.176 (3H,m)。
实施例 6: IST_009_019的合成
Figure imgf000012_0001
2-羟基 -4-丁基 -2, 4, 6-环庚三烯小酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以致换瓶中空气。 N2保护下加入氢氧化钾(0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体(0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和正溴丁烷 ( 0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升 温继续反应 lh以上, 然后流加稀盐酸调 pH至酸性, 调毕, 充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情 况, 由此得到正丁基环戊二烯。
第二步:
搅拌下, 往正丁基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15 °C, 约 lhr 滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜10min 后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有机相在 35 °C左右水温下旋蒸除去溶媒, 得到的残留液即为二氯双环酮。
第三步:
具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40°C以下后加入 200ml乙酸乙酯, 200ml水 + 10ml浓盐酸, 萃取分层, 弃去水相, 有机相用 200ml水再洗涤 2次。 旋干有机溶剂, 残留物减 压蒸馏, 压力 -O. lMPa,外温 150〜180QC, 馏份温度 115〜120QC, 得到约 25克产 品, 将产品溶解在 150ml正己烷和 10ml乙醇的混合液中, 加热至 70QC完全溶 解, 然后放在低温槽中降温至 -5QC, 有大量白色晶体析出, 过滤, 滤饼用正己烷 洗涤 为 2-羟基 -4-丁基 -2, 4, 6-环庚三烯 -1-酮的,其结构式为:
Figure imgf000013_0001
2-羟基 -4-丁基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.267-7.309 (1H, m), 7.142(1H, s),7.070-7.092(lH, d,J=l l), 6.910-6.931(1H, d,J=10.5), 2.54 9-2.580(2H, m), 1.503-1.564(2H,m), 1.253-1.312(2H,m),0.860-0.889(3H,m).
实施例 7: 1ST— 009— 025的合成
Figure imgf000013_0002
2-羟基 -4-对氯苄基 -2, 4, 6-环庚三烯小酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以致换瓶中空气。 N2保护下加入氢氧化钾(0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体(0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和对氯苄溴 ( 0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升 温继续反应 lh以上, 然后流加稀盐酸调 pH至酸性, 调毕, 充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 由此得到对氯苄溴基环戊二烯。
第二步:
搅拌下, 往对氯苄溴基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜 1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15 °C, 约 lhr滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜 lOmin后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有 机相在 35 °C左右水温下旋蒸除去溶媒, 得到的残留液即为二氯双环酮。 具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40 °C以下后加入 100ml二氯甲烷, 200ml水 +3ml浓盐酸, 萃取分层, 弃去水相, 有机相再用 100ml水洗涤 2次。有机相用 1M的氢氧化钾 水溶液调制水相呈强碱性, 萃取分离, 弃去有机相, 水相用二氯甲烷再洗涤两次 100ml*2.水相中加入 100ml二氯甲烷, 然后用 2M稀盐酸跳 PH值至酸性, 萃取 分层,有机相再用蒸馏水洗涤两次,旋干有机相得产物。 HPLC显示纯度为 99%。
-羟基 -4-对氯苄基 -2, 4, 6-环庚三烯 -1-酮, 其结构式为:
Figure imgf000014_0001
2-羟基 -4-对氯苄基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.304-7.323 (2H, d,J=9.5), 7.213-7.284(1H, m),7.183(lH, s), 7.157-7.139(2H, d,J=9.5), 7.071-7.049(1H, d,J=l 1),6.986-7.006(1H, d,J=10), 3.953(2H, s)。
实施例 8: 1ST— 009— 028的合成
Figure imgf000014_0002
2-羟基 -4-对氟苄基 -2, 4, 6-环庚三烯小酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以置换瓶中空气。 N2保护下加入氢氧化钾(0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体(0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和对氟苄溴 (0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升 温继续反应 lh以上, 然后流加稀盐酸调 pH至酸性, 调毕, 充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 由此得到对氟苄溴基环戊二烯。
第二步:
搅拌下, 往对氟苄溴基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜 1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15°C, 约 lhr滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜 lOmin后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有 机相在 35°C左右水温下旋蒸除去溶媒, 得到的残留液即为二氯双环酮。
第三步:
具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40 °C以下后加入 100ml二氯甲烷, 200ml水 +3ml浓盐酸, 萃取分层, 弃去水相, 有机相再用 100ml水洗涤 2次。有机相用 1M的氢氧化钾 水溶液调制水相呈强碱性, 萃取分离, 弃去有机相, 水相用二氯甲烷再洗涤两次 100ml*2.水相中加入 100ml二氯甲烷, 然后用 2M稀盐酸调 PH值至酸性, 萃取 分层, 有机相再用蒸馏水洗涤两次, 旋干有机相得粗产品, 将粗产品溶解在约 50ml乙醇中, 放入冰箱静置过夜, 有固体析出, 过滤, 滤饼用约 5〜10ml乙醇 洗涤, 旋干溶剂得产品, HPLC显示纯度 98%。 NMR鉴定为 2-羟基 -4-对氟苄
基 -2, 4, 6-环庚三烯 -1-酮, 其结构式为:
Figure imgf000015_0001
2-羟基 -4-对氟苄基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz)
7.306-7.325(2H, d,J=9.5), 7.183-7.285(1H, m),7.157(lH, s), 7.120-7.139(2H, d,J=9.5), 7.067-7.089(lH, d,J=l l),6.973-6.993(lH, d,J=10), 3.946(2H, s)。
实施例 9: IST_009_030 (2-羟基 -4-正辛基 -2, 4, 6-环庚三烯 -1-酮) 的合成
Figure imgf000016_0001
2-羟基 -4-正辛基 -2, 4, 6-环庚三烯小酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以置换瓶中空气。 N2保护下加入氢氧化钾(0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体 (0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和正溴辛烷 ( 0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升 温继续反应 lh以上, 然后流加稀盐酸调 pH至酸性, 调毕, 充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 由此得到正辛基环戊二烯。
第二步:
搅拌下, 往正辛基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15 °C, 约 lhr 滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜10min 后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有机相在 35 °C左右水温下旋蒸除去溶媒, 得到的残留液即为二氯双环酮。
第三步:
具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40°C以下后加入石油醚, 有大量固体析出, 倒出澄清液体, 固体再用石油醚洗涤一次, 滤出有机相, 合并有机相, 弃去固体。 往有机相中加 入约 200毫升蒸馏水洗涤,萃取分层,弃去水相。往有机相(上层)中加入 200ml 水搅拌下加入 3M的氢氧化钾水溶液 150ml, 然后萃取分液。 水层再用石油醚洗 涤一次, 弃去石油醚相, 然后往水层中加入 200ml石油醚, 搅拌下加入 3M的稀 盐酸中和至 PH值 1〜2,萃取分液,有机层再用水洗涤一次,硅胶柱分离,产物, HPLC显示纯度为 99%。 NMR鉴定为: 2-羟基 -4-正辛基 -2, 4, 6-环庚三烯 -1-酮,
其结构式为:
Figure imgf000017_0001
2-羟基 -4-正辛基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.250-7.273 (1H, m), 7.133(1H, s),7.062-7.083(lH, d,J=10.5), 6.097-6.927(lH, d,J=10),
2.556-2.571(2H, m), 1.530-1.544(2H, m),1.214-1.247(10H,m), 0.814-0.841(3H,m)。
实施例 10: IST_009_031的合成
Figure imgf000017_0002
2—羟基 -4-1-氟丙基 -2, 4, 6-环庚三烯 -1-酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以致换瓶中空气。 N2保护下加入氢氧化钾(0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体(0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和 1-氟 -3-溴丙 烷(0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然 升温继续反应 lh以上,然后流加稀盐酸调 pH至酸性,调毕,充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情 况, 由此得到 3-氟丙基环戊二烯。
第二步:
搅拌下,往 3-氟丙基环戊二烯的正己烷溶液中加入二氯乙酰氯 ( 0.7〜1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15 °C, 约 lhr 滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜10min 后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有机相在 35 °C左右水温下旋蒸除去溶媒, 得到的残留液即为二氯双环酮。 第三步:
具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。
反应毕, 降温至 40°C以下后加入 200ml乙酸乙酯, 200ml水 + 10ml浓盐酸, 萃取分层, 弃去水相, 有机相再用 200ml水洗涤 2次。 旋干有机溶剂, 残留物减 压蒸馏, 压力 -O.lMPa,外温 140〜150QC, 馏份温度 130-135QC, 得到黄色液体产 品, NMR鉴定为: 2-羟基 -4-1-氟丙基 -2, 4, 6-环庚三烯 -1-酮。
2-羟基 -4-1-氟丙基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.277-7.319 (1H, m), 7.170(1H, s),7.083-7.105(lH, d,J=l l), 6.928-6.948(lH, d,J=10), 4.484-4.508(lH, m), 4.390-40401(lH, m), 2.650-2.681(2H,m), 1.892-1.997(2H,m)。
实施例 11: IST_009 033的合成
Figure imgf000018_0001
2-羟基 -4-正十四烷基 -2, 4, 6-环庚三烯 -1-酮的制备
第一步:
室温下于 500ml三口反应瓶中加入 DMSO150ml, 开搅拌, 然后通 N230min 以置换瓶中空气。 N2保护下加入氢氧化钾 (0.3mOl,leq), 继续在 N2保护下搅拌 0.5小时, 30min内流加环戊二烯单体 (0.8〜1.2eq)。 流加毕, N2保护下继续搅 拌 lh。 后开冷冻降温至 -10°C左右, 往三口瓶中滴加正己烷 150ml和溴代十四烷 (0.8〜1.2eq) 的混合溶液, 时间约 lh, 控制温度不高于 20°C。 流加毕, 自然升 温继续反应 lh以上, 然后流加稀盐酸调 pH至酸性, 调毕, 充分搅拌 5〜10min 后分液, 水层用 150ml正己烷再萃取一次, 合并有机层并用水 250mlx2洗涤至 水相呈中性, 40g无水硫酸钠干燥至液体澄清, 滤除固体, 有机相 (约 400ml) 加入到 1000ml三口瓶中, 20±2°C静置 7〜20hr使其异构化, GC测定异构化情况, 由此得到正十四烷基环戊二烯。
第二步:
搅拌下, 往正十四烷基环戊二烯的正己烷溶液中加入二氯乙酰氯 (0.7〜 1.5eq), 降温至 -15〜10°C左右滴加三乙胺 (0.8〜1.5eq), 控制温度不超过 15°C, 约 lhr滴完, 继续保温反应 lh, 然后流加稀盐酸调 pH中性或微酸性, 搅拌 5〜 lOmin后分液, TLC (展开剂: PE) 检查有机相和水相中的产物情况。 然后有 机相在 35°C左右水温下旋蒸除去溶媒, 得到的残留液即为二氯双环酮。
第三步:
具冷凝管的 1000ml三口瓶中加入上一步制备的二氯双环酮,依次加入 125ml 叔丁醇, 20ml醋酸和 25ml水,开搅拌升温至 75〜80°C,流加 85ml(98%, 0.675mol) 三乙胺, 加毕 (约 lhr), 计时保温反应过夜, TLC (展开剂: PE) 判断反应终 点。 反应毕, 降温至 40°C以下后加入 100ml石油醚, 100ml水, 萃取分层, 弃 去水相。 有机相拌硅胶, 过柱, 先用纯石油醚淋洗掉小极性的杂质点, 然后用 PE:EA=10:1淋洗出产 -羟基 -4-正十四烷基 -2, 4, 6-环庚三烯
-1-酮, 其结构式为:
Figure imgf000019_0001
2-羟基 -4-正十四烷基 -2, 4, 6-环庚三烯 -1-酮: δΗ (DMSO, 500 MHz) 7.273-7.340 (1H, m), 7.145(1H, s),7.073-7.095(lH, d,J=l l), 6.920-6.940(lH, d,J=10), 2.506-2.587(2H, m),1.561(2H,m), 1.227-1.275(22H,m),0.835-0.861(3H,m)。
实施例 12: p-扁柏酚衍生物体外抗菌活性(MICs)
用试管二倍稀释法测定 β-扁柏酚系列衍生物对不同种类细菌的体外最小抑 菌浓度。 结果如表 1、 2、 3和 4所示, 表 1、 2、 3和 4显示 β-扁柏酚衍生物具有 广谱的抗菌活性, 对动物重要病原性细菌 (如产气荚膜梭菌、 金黄色葡萄球菌、 大肠杆菌、 沙门氏菌、 鸭疫里默氏杆菌、 副猪嗜血杆菌、 弧菌和链球菌等)均表 现出很好的抑制活性,尤其是衍生物 IST_009_001和 IST_009_003等的抗菌活性 强于先导化合物 IST_001_002 ( β -扁柏酚)。
Figure imgf000019_0002
IST—009—004 12.5 12.5 ND ND
IST—009—018 3.13 3.13 ND ND
IST_009_019 12.5 6.25 ND ND
IST—009—030 25 12.5 12.5 12.5
IST_009_031 6.25 6.25 ND ND 注: ND代表未测试。
表 2: β-扁柏酚衍生物对大肠杆菌和沙门氏菌的体外最小抑菌浓度 (MIC, g/ml )
Figure imgf000020_0002
表 3 : β-扁柏酚衍生物对副猪嗜血杆菌和鸭疫里默氏杆菌的体外最小抑菌浓度(MIC, g/ml )
Figure imgf000020_0003
注: ND代表未测试。
Figure imgf000020_0001
IST—009—018 25 25 > 100 12.5
IST_009_019 50 50 25 > 100
IST—009—025 > 100 > 100 25 25
IST—009—028 100 100 25 25
IST—009—030 > 100 > 100 25 25
实施例 13: p-扁柏酚衍生物在肉鸡料中的应用效果
598羽 30日龄快大型黄羽肉鸡 (母苗) 按表 5进行分组, 各试验组分别添 加 β-扁柏酚衍生物或 /和硫酸粘杆菌素, 试验期自由采食和饮水, 伺养 14天。 统 计并比较试验期各组的生产性能,试验结果显标 β-扁柏酚衍生物 IST_009_001和
5 IST_009_003等能提高试验鸡的增重和伺料转化效率 (表 6)。
表 5 β-扁柏酚衍生物在肉鸡料中应用效果试验的分组设计
Figure imgf000021_0001
表 6 β-扁柏酚衍生物在肉鸡料中应用效果的试验结果
平均增重 平均日增重
添加物质 齐 Ll量 (ppm) 总耗料(kg) 料肉比
(g) (g/d*只)
- - 475.16 54.67 32.01 3.049
IST_009_001 5 547.21 55.12 33.52 2.808
IST—009—001 15 523.38 57.84 34.53 2.889
IST_009_003 40 502.05 58.05 36.21 2.862
IST_009_001+硫酸粘
10+20 528.50 57.63 36.82 2.795 杆菌素
- - 517.00 60.27 36.67 2.812
IST—009—001 5 516.79 61 37.75 2.886
IST—009—001 15 517.17 58.03 36.94 2.807 IST—009—003 40 449.90 57.71 34.19 2.952
IST_009_001+硫酸粘
10+20 507.00 60.39 38.18 2.825 杆菌素
- - 507.24 60.55 35.13 2.980
IST—009—001 5 520.00 58.85 36.93 2.846
IST—009—001 15 525.50 57.61 37.5 2.741
IST_009_003 40 534.50 58.17 37.14 2.868
IST_009_001+硫酸粘
10+20 527.00 56.61 37.64 2.685 杆菌素
实施例 14: P-扁柏酚衍生物对断奶仔猪腹泻的控制效果
80头 25日龄刚断奶仔猪如表 Ί随机分成 8个处理组, 每个处理组 10头猪。 按照表中剂量在无抗生素添加的基础日粮中连续添加 IST_009_001、硫酸粘杆菌 素或 IST_001_002, 试验期间保温、 自由采食和饮水, 试验期 10天, 统计试验 期各试验组的平均日腹泻率 (%), 结果显示 (表 7)在伺料中添加 IST_009_001 可以显著降低试验猪的腹泻率,且 IST_009_001 30ppm试验组的效果明显优级于 硫酸粘杆菌素和 1ST 001 002试验组。
表 7: β-扁柏酚衍生物对断奶仔猪腹泻的控制
Figure imgf000022_0001
实施例 15: P-扁柏酚衍生物对鸭疫里默氏杆菌攻攻击感染的保护效果
100只 16日龄樱桃谷肉鸭如表 8随机分成 10个试验组, 肌肉注射攻击感染 鸭疫里默氏杆菌 5x l07CFU/鸭, 攻毒的同时经肌肉注射给药。然后观察试验鸭的 发病和死亡情况,死亡鸭剖检确认是否是鸭疫里默氏杆菌感染导致的死亡,观察 期 Ί天。试验结束时处死所有试验鸭,剖检确认发病情况。统计结果如表 8所示, 表 8显示 β-扁柏酚衍生物 IST_009_001能保护鸭疫里默氏杆菌对鸭的攻击感染。
表 8 : 扁柏酚衍生物对鸭疫里默氏 二菌攻攻击感染的 1呆护效果
组别 动物数量 攻毒剂量 药物 剂量 发病率 死亡率
(只) ( CFU/bird) (mg/kg体重) ( %) ( %)
1 20 - - - 0 0
2 20 5χ 107 - - 100 65 20 5χ107 头孢噻肟 10 25 0
20 5χ107 IST—009—001 10 40 0
20 5χ107 IST—009—001 20 25 0

Claims

权利要求书
1、 β-扁柏酚衍生物, 其结构式如式 ( I ) 所示:
Figure imgf000024_0001
( I )
其中 R 为正丙基、 正戊基、 苄基、 仲丁基、 乙基、 正丁基、 对氯苄基、 对 氟苄基、 正辛基、 1-氟丙基或正十四烷基
2、 权利要求 1所述的 β-扁柏酚衍生物中的任意一种在制备动物专用抗菌剂 或伺用抗菌生长促进剂中的应用。
3、 根据权利要求 2所述的应用, 其特征在于, 所述的动物为各个生长阶段 的猪、 鸡、 鸭、 鹅、 肉牛、 奶牛、 羊、 鱼、 虾、 狐、 貂或貉。
4、 根据权利要求 2所述的应用, 其特征在于, 所述的 β-扁柏酚衍生物, 其 在动物伺料中的添加剂量为 0.1〜200ppm动物伺料。
5、 根据权利要求 2所述的应用, 其特征在于, 所述的动物专用抗菌剂为治 疗各种动物敏感菌感染导致的疾病时, 其应用剂量为 l-30mg/kg体重。
PCT/CN2014/070603 2013-12-31 2014-01-14 β-扁柏酚衍生物及其在制备动物专用抗菌剂以及饲用抗菌生长促进剂中的应用 WO2015100799A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2934581A CA2934581A1 (en) 2013-12-31 2014-01-14 .beta.-hinokitiol derivatives and applications thereof in preparation of animal antibacterial agents and antibacterial growth promoters used in feed
BR112016013801A BR112016013801A2 (pt) 2013-12-31 2014-01-14 Derivados de ss-hinoquitiol e suas aplicações na preparação de agentes antibacterianos de animais e promotores de crescimento antibacterianos utilizados na alimentação
EP14875937.6A EP3085685A4 (en) 2013-12-31 2014-01-14 BETA-HINOKITOL DERIVATIVES AND USES THEREOF IN THE MANUFACTURE OF A SPECIAL ANTIBACTERIAL AGENT FOR ANIMALS AND ANIMALIZED GROWTH PROMOTERS FOR FEED AGENTS
US15/108,726 US20160316790A1 (en) 2013-12-31 2014-01-14 Beta-hinokitiol derivatives and applications thereof in preparation of animal antibacterial agents and antibacterial growth promoters used in feed

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310751901.XA CN103739471B (zh) 2013-12-31 2013-12-31 β-扁柏酚衍生物及其在制备动物专用抗菌剂以及饲用抗菌生长促进剂中的应用
CN201310751901.X 2013-12-31

Publications (1)

Publication Number Publication Date
WO2015100799A1 true WO2015100799A1 (zh) 2015-07-09

Family

ID=50496564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/070603 WO2015100799A1 (zh) 2013-12-31 2014-01-14 β-扁柏酚衍生物及其在制备动物专用抗菌剂以及饲用抗菌生长促进剂中的应用

Country Status (6)

Country Link
US (1) US20160316790A1 (zh)
EP (1) EP3085685A4 (zh)
CN (2) CN104922100B (zh)
BR (1) BR112016013801A2 (zh)
CA (1) CA2934581A1 (zh)
WO (1) WO2015100799A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109512998A (zh) * 2016-03-04 2019-03-26 广州英赛特生物技术有限公司 含氧碳氢衍生物的酯化衍生物作为多粘菌素的协同增效剂的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547365A (en) * 1982-11-08 1985-10-15 Shiseido Company Ltd. Waving lotion for cold waving
JPH0475745B2 (zh) * 1989-02-09 1992-12-01 Taiyo Kagaku Kk
US6387417B1 (en) 1999-08-23 2002-05-14 Kazuo Iwai Bactericide against vancomycin resistant enterococcus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5984809A (ja) * 1982-11-08 1984-05-16 Shiseido Co Ltd パーマネントウェーブ用剤第1剤の製造方法
DE19510229A1 (de) * 1995-03-23 1996-09-26 Keppler Bernhard K Priv Doz Dr Antimikrobiell und antineoplastisch wirkende Bismutverbindungen mit Tropolon-, Thiosemicarbazon- und Dithiocarbazonsäureesterverbindungen und diese enthaltende Arzneimittel
US6025312A (en) * 1995-06-30 2000-02-15 P & Pf Co., Ltd. Antibacterial, bactericidal and antiseptic agent, dermatologic preparation and detergent composition
AU2001258829A1 (en) * 2000-05-25 2001-12-03 Nippon Shinyaku Co. Ltd. Tropolone derivatives and pharmaceutical compositions
US9790158B2 (en) * 2012-06-22 2017-10-17 University Of Connecticut Substituted tropolone derivatives and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547365A (en) * 1982-11-08 1985-10-15 Shiseido Company Ltd. Waving lotion for cold waving
JPH0475745B2 (zh) * 1989-02-09 1992-12-01 Taiyo Kagaku Kk
US6387417B1 (en) 1999-08-23 2002-05-14 Kazuo Iwai Bactericide against vancomycin resistant enterococcus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3085685A4

Also Published As

Publication number Publication date
EP3085685A1 (en) 2016-10-26
EP3085685A4 (en) 2016-12-28
CN104922100B (zh) 2018-04-06
CN103739471A (zh) 2014-04-23
US20160316790A1 (en) 2016-11-03
BR112016013801A2 (pt) 2017-08-08
CN104922100A (zh) 2015-09-23
CA2934581A1 (en) 2015-07-09
CN103739471B (zh) 2016-04-13

Similar Documents

Publication Publication Date Title
GB2528793B (en) Triazine compound for combating coccidiosis in chickens
CN102001980B (zh) 一种沃尼妙林盐酸盐的出料方法
CN103880712B (zh) 二氨基胍衍生物及其在制备动物饲用生长促进剂中的应用
US20170332666A1 (en) Application of p-methyl benzoic acid or salts thereof as additives for animal feed
WO2015100799A1 (zh) β-扁柏酚衍生物及其在制备动物专用抗菌剂以及饲用抗菌生长促进剂中的应用
CN106692138A (zh) N-苄基咪酰胺衍生物作为多粘菌素类抗生素协同增效剂的应用
CN101838214A (zh) 一种饲料添加剂dl-苏氨酸螯合铜的制备方法
JPS6043097B2 (ja) 飼料利用効率改善剤
JP2022506755A (ja) 動物飼料添加剤の調製におけるアスパラギン酸誘導体の用途
CN101486686B (zh) 具有喹喔啉母环的两种化合物及其制备方法
EP2992884A1 (en) Use of enrofloxacin salt in preparing swine oral preparation
WO2020143040A1 (zh) 色氨酸衍生物及其应用
RU2502511C1 (ru) Средство для лечения кокцидиозов в ветеринарии
US3773943A (en) Alpha,alpha,alpha-trifluoro-6-substituted-5-nitro-m-toluic acid,5'-nitrofurylidene hydrazide compounds as growth promotants
WO2020124351A1 (zh) 一种谷氨酰胺衍生物在制备动物饲料添加剂中的应用
CN107889939B (zh) 一种甘氨酸葡萄糖胞外多糖复配饲料添加剂
CN101597236B (zh) 苏氨酸硒及其制备方法和应用
KR101205713B1 (ko) 1-[2-(4-니트로-페닐)-벤즈옥사졸-5-일]-프로판-1-온을 유효성분으로 함유하는 톡소포자충 및 콕시디움에 기인한 질환의 예방 및 치료용 조성물
AU2018450480B2 (en) Applications of diphenylpropenone compound in preparing animal feed additive or animal feed
US20210267917A1 (en) Food supplement and composition comprising choline butyrate salt and/or butyrylcholine
RU2778986C9 (ru) Применение ацилированных производных аминокислоты для приготовления кормовой добавки для животных
RU2778986C1 (ru) Применение ацилированных производных аминокислоты для приготовления кормовой добавки для животных
WO2020097779A1 (zh) 一种氨基酸的酰基化衍生物在制备动物饲料添加剂中的应用
WO2020177100A1 (zh) γ-季铵基丁酸酯类化合物在制备动物饲料添加剂中的应用
CN101602683B (zh) 苏氨酸钴及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14875937

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2014875937

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014875937

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2934581

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016013801

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 15108726

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112016013801

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160615